Top Page
Impedimed Limited
(OTC:IPD)
Impedimed Limited (IPD) vs. iShares MSCI Australia ETF (EWA)
Impedimed Limited Business Overview & Revenue Model
Impedimed Limited Earnings Call Summary
Impedimed Limited Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 11.54M | 10.32M | 11.34M | 10.57M | 8.41M | 5.74M | Gross Profit |
| 10.14M | 9.01M | -13.65M | -13.35M | -12.20M | -12.89M | EBIT |
| -1.04M | -19.04M | -22.85M | -21.23M | -23.02M | -25.51M | EBITDA |
| -21.08M | -22.05M | -20.49M | -18.65M | -20.70M | -24.07M | Net Income Common Stockholders |
| -21.22M | -19.79M | -20.52M | -19.87M | -20.71M | -21.38M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 17.69M | 24.63M | 45.71M | 40.73M | 19.68M | 19.66M | Total Assets |
| 39.19M | 46.99M | 68.74M | 58.70M | 34.20M | 33.06M | Total Debt |
| 1.05M | 1.14M | 1.45M | 170.00K | 474.00K | 871.00K | Net Debt |
| -16.65M | -23.49M | -44.26M | -40.56M | -19.21M | -18.79M | Total Liabilities |
| 6.87M | 6.24M | 7.86M | 7.66M | 8.69M | 5.70M | Stockholders Equity |
| 32.32M | 40.74M | 60.88M | 51.04M | 25.51M | 27.36M |
| Cash Flow | Free Cash Flow | ||||
| -19.72M | -20.89M | -24.09M | -20.89M | -15.71M | -21.38M | Operating Cash Flow |
| -18.29M | -17.79M | -18.05M | -15.66M | -13.26M | -19.22M | Investing Cash Flow |
| -2.02M | -3.10M | -6.04M | -5.22M | -2.46M | -2.16M | Financing Cash Flow |
| -462.00K | -481.00K | 27.93M | 39.92M | 16.47M | 30.16M |
Impedimed Limited Technical Analysis
Impedimed Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.38B | 3.40 | -45.06% | 3.28% | 16.75% | -0.02% | |
50 Neutral | AU$51.90M | ― | -8.08% | ― | -5.62% | -225.71% | |
50 Neutral | AU$64.88M | ― | -51.08% | ― | 10.22% | -2.94% | |
| $23.06M | ― | -50.50% | ― | ― | ― | ||
48 Neutral | AU$152.22M | ― | -58.61% | ― | ― | -74.88% | |
44 Neutral | AU$118.92M | ― | -35.20% | ― | 4.68% | -155.42% | |
41 Neutral | AU$32.03M | ― | -135.33% | ― | -27.58% | 33.69% |
Impedimed Limited Corporate Events
Impedimed Limited announced a change in the director’s interest notice, specifically regarding Ms. Christine Emmanuel-Donnelly’s holdings. The change involved an acquisition of 306,446 ordinary shares in the Donnelly Superannuation Fund, increasing her total holdings in this fund to 1,736,255 shares. This transaction, conducted as an on-market trade, reflects the director’s increased investment in the company, potentially signaling confidence in Impedimed’s future prospects and stability.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited reported a record revenue of A$3.4 million for the third quarter of FY25, alongside a significant increase in annual recurring revenue and total contracted value. The company appointed Scott Long as the new SVP of Sales, aiming to enhance sales operations and market penetration. Despite a decrease in total SOZO unit sales, the company saw a 10% increase in US sales and maintained low churn rates. ImpediMed is focusing on converting leads into sales, supported by increased media activity and conference participation. The company ended the quarter with a cash balance of A$27.9 million, bolstered by a growth capital facility drawdown.
ImpediMed Limited has announced a change in the director’s interest notice, specifically for Ms. Christine Emmanuel-Donnelly. The change involves the issuance of shares in lieu of 30% of director fees for the quarter ended 31 March 2025. This adjustment reflects a strategic decision to align director compensation with company performance, potentially impacting the company’s financial management and shareholder relations.
Impedimed Limited announced a change in the director’s interest, with Fiona Bones acquiring an additional 197,647 ordinary shares, bringing her total to 1,506,230 shares. This acquisition was made through the issue of shares in lieu of 30% of director fees for the quarter ended March 31, 2025, reflecting a strategic approach to compensation and potentially strengthening the director’s alignment with shareholder interests.
ImpediMed Limited has announced a change in the director’s interest, with Mr. Andrew Grant acquiring an additional 197,647 ordinary shares, bringing his total to 2,506,230 shares. This acquisition was made through the issuance of shares in lieu of 30% of his director fees for the quarter ended March 31, 2025, reflecting a strategic move to align director compensation with company performance, potentially impacting stakeholder perceptions positively.
Impedimed Limited announced a change in the director’s interest, with Ms. Janelle Delaney acquiring additional ordinary shares. The acquisition was part of a compensation arrangement where shares were issued in lieu of 30% of her director fees for the quarter ended March 31, 2025. This move reflects the company’s strategy to align director compensation with shareholder interests, potentially impacting the company’s governance and financial strategies.
Impedimed Limited has announced the issuance of 815,481 fully paid ordinary shares to its executives as part of their remuneration for the quarter ended March 31, 2025. This move is part of the company’s Executive Share Plan and reflects its strategy to align executive compensation with company performance, potentially impacting its financial structure and stakeholder interests.
Impedimed Limited announced the issuance of 942,353 ordinary fully paid shares to its non-executive directors as part of the Non-Executive Director Share Plan, covering 30% of director fees for the quarter ending March 31, 2025. This move is part of the company’s strategy to align the interests of its directors with shareholders, potentially impacting the company’s governance and financial structure.
ImpediMed Limited announced that it will release its quarterly cash flow report for the period ending March 31, 2025, on April 30, 2025. The company will host an investor conference call on the same day, led by CEO Dr. Parmjot Bains and CF&OO McGregor Grant, providing stakeholders an opportunity to engage with management and discuss the company’s financial performance and outlook.
ImpediMed Limited has announced a change in the address of its Sydney share registry office, which is now located at Liberty Place, Level 41, 161 Castlereagh Street, Sydney NSW 2000. This move is part of the company’s ongoing operational adjustments, although the telephone numbers and postal address remain unchanged. This update is approved by the Company Secretary and reflects ImpediMed’s commitment to maintaining efficient operations and communication with stakeholders.
ImpediMed Limited has announced that the recent U.S. tariffs on imports are not expected to have a significant impact on its business or supply chain in the short to medium term. The company’s SOZO device is manufactured in the U.S. with many components sourced locally, and it maintains a sufficient inventory to mitigate potential supply chain disruptions. ImpediMed will continue to monitor the situation and update stakeholders if necessary.
Impedimed Limited announced the cessation of certain securities, including 4,362,750 options that expired without exercise and 201,962 performance rights that lapsed due to unmet conditions as of March 31, 2025. This announcement may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial management and strategic direction.